Researchers design delivery system to treat premature infants with NEC

July 11, 2018, Nationwide Children's Hospital

Most of the time, we think biofilms are bad news. And when pathogenic microbes form biofilms, they are. The biofilms created by pathogenic microbes create fortresses that make them resistant to attack by the immune system and to current antimicrobial treatments. These fortresses make eradicating infections difficult.

But what if you could use biofilms for good? That's just what Gail Besner, MD, Steve Goodman, Ph.D., Michael Bailey, Ph.D., Lauren Bakaletz, Ph.D., and their teams at Nationwide Children's Hospital are investigating.

They have developed Lactobacillus reuteri biofilm formulations that protect against experimental necrotizing enterocolitis (NEC), first described in Journal of Pediatric Surgery in 2016. A new iteration of the technology may help further reduce the incidence of NEC.

"NEC is a devastating problem for premature infants. Despite decades of research, 10 percent of infants born under 1500 g will develop NEC, and we haven't made significant progress in the prevention or treatment over the years—mortality remains as high as 30 percent for these babies," says Dr. Besner, chief of Pediatric Surgery at Nationwide Children's.

Bacterial colonization of the infant's gut is critical to healthy development. Although variability exists among individuals, premature infants tend to have reduced microbiome diversity and stability, and increased numbers of pathogenic Gammaproteobacteria, according to the publication.

"Using probiotics to treat NEC is not a new idea, but administering free-living probiotics has had variable results in ," explains Dr. Besner, also a professor of Surgery and Pediatrics at The Ohio State University. "Our idea was to develop a safe, effective delivery mechanism to support a one-dose treatment to prevent NEC. In our animal models of the disease, this is what we appear to have accomplished."

To create the biofilm, cultures of L. reuteri are introduced to porous, biocompatible, biodegradable 50 μm diameter dextranomer microspheres. During a brief incubation, the bacteria adhere to the microspheres and form a biofilm. In the biofilm state, the probiotics have increased resistance to gastric acidity and increased adherence to the gastrointestinal mucosa compared to free-floating bacteria.

Now, the team has published the results of their latest iteration of the technology—testing the effects of enhancing the microspheres with sucrose or maltose as diffusible cargo. The study, published in American Journal of Physiology, reports enhanced performance of the single dose L. reuteri biofilm in experimental NEC.

According to the authors, in addition to reducing the incidence of NEC in animals, the enhanced formulation improved animal survival, reduced intestinal mucosal barrier breakdown and limited intestinal inflammation. The L. reuteri microspheres loaded with maltose also augmented the persistence of numerous Lactobacillus species in the intestinal tract and shifted the gut microbiome to be more similar to that of breast-fed babies.

"Given the microbiome disruption observed in preterm infants who go on to develop NEC, a treatment that preserves the microbiome holds great promise as an intervention to prevent NEC," says Dr. Besner, who is senior author of the recent publication. "Furthermore, our novel probiotic delivery system limits the expansion of pathogenic bacteria such as Enterobacter species, providing further evidence that it attenuates detrimental NEC-induced dysbiosis."

All of the components—the probiotic, the microsphere, the sucrose/maltose—used in the proposed intervention are "Generally Recognized as Safe" (GRAS) by the U.S. Food and Drug Administration (FDA). The scientists hope that this will be an advantage as they begin to work to develop clinical trials using the L. reuteri preparation.

"The use of these microspheres represents an exciting development in improved probiotic administration. As we continue to learn more about the human microbiome and its relationship to health and disease, probiotic administration may play an increasingly important role in disease prevention and management—not just for the application to NEC," says Dr. Besner.

Previous clinical trials of probiotics to prevent NEC have had variable results. Dr. Besner and her colleagues believe that the novel delivery system that they have developed will offer significant advantages over L. reuteri delivered in its free-living form. To that end, they are in talks with the FDA to design a clinical trial to test the delivery system in humans.

Drs. Besner, Goodman, Bailey and Bakaletz are the scientific founders of a preclinical stage company - Scioto Biosciences - created to bring microbiome therapeutics to the marketplace.

Explore further: L. reuteri DSM17938 effective for colic in breastfed infants

More information: Journal of Pediatric Surgery (2018). DOI: 10.1152/ajpgi.00078

Related Stories

L. reuteri DSM17938 effective for colic in breastfed infants

December 27, 2017
(HealthDay)—Lactobacillus reuteri DSM17938 is effective for breastfed infants with colic, according to a meta-analysis published online Dec. 26 in Pediatrics.

Lactobacillus reuteri may have multiple benefits as a probiotic in premature infants

June 9, 2015
A new study finds that supplementing enteral nutrition with Lactobacillus reuteri (L. reuteri) DSM 17938 as a probiotic may reduce the risk of necrotizing enterocolitis (NEC) in premature infants. NEC is a condition where ...

Study examines probiotics to prevent or treat excessive infant crying

October 7, 2013
There still appears to be insufficient evidence to support using probiotics (Lactobacillus reuteri) to manage colic or to prevent crying in infants, especially in formula-fed babies, but it may be an effective treatment for ...

Research opens possibility of reducing risk of gut bacterial infections with next-generation probiotics

August 9, 2017
A team of researchers is exploring the possibility that next-generation probiotics – live bacteria that are good for your health – would reduce the risk of infection with the bacterium Clostridium difficile. In laboratory-grown ...

Recommended for you

Sucking your baby's pacifier may benefit their health

November 16, 2018
Many parents probably think nothing of sucking on their baby's pacifier to clean it after it falls to the ground. Turns out, doing so may benefit their child's health.

Newborn babies' brain responses to being touched on the face measured for the first time

November 16, 2018
A newborn baby's brain responds to being touched on the face, according to new research co-led by UCL.

No link between 'hypoallergenic' dogs and lower risk of childhood asthma

November 15, 2018
Growing up with dogs is linked to a lower risk of asthma, especially if the dogs are female, a new study from Karolinska Institutet and Uppsala University in Sweden shows. However, the researchers found no relation between ...

Study shows changes in histone methylation patterns in nutritionally stunted children

November 13, 2018
An international team of researchers has found changes in histone methylation patterns in nutritionally stunted children. In their paper published in Proceedings of the National Academy of Sciences, the group describes their ...

Your 6-month-old isn't sleeping through the night? Relax

November 12, 2018
(HealthDay)—If your 6-month-old still wakes up at 2 a.m., a new study suggests you don't lose any additional sleep worrying about it.

New exercise guidelines: Move more, sit less, start younger

November 12, 2018
Move more, sit less and get kids active as young as age 3, say new federal guidelines that stress that any amount and any type of exercise helps health.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.